Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × trametinib × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Head & Neck 1 Gastrointestinal 1 Endocrine 1 Dermatologic 1

Conditions

Neoplasms 1 Melanoma 1

Interventions

pembrolizumab 5 Nivolumab 3 cemiplimab 2 Vemurafenib 2 Ipilimumab 2 trametinib 1 relatlimab 1 mogamulizumab 1 lifileucel 1 larotrectinib 1 entrectinib 1 encorafenib 1 dabrafenib 1 cobimetinib 1 binimetinib 1 atezolizumab 1 Vorinostat 1 Melphalan 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01682083 2023-08-30

COMBI-AD

Novartis

Phase 3 Completed

870 enrolled 13 charts 1 FDA

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡